Text Size

Open-Label Trial of the Use of Minocycline in the Treatment of Asthma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2007 by State University of New York - Downstate Medical Center.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
State University of New York - Downstate Medical Center
ClinicalTrials.gov Identifier:
NCT00536042
First received: September 26, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted

September 26, 2007
September 26, 2007
October 1997
Not Provided
Improvement in FEV1 on spirometry [ Time Frame: one year ]
Same as current
No Changes Posted
  • decrease in total serum IgE [ Time Frame: one year ]
  • decrease in oral steroid requirements [ Time Frame: one year ]
  • improvement in quality of life scores [ Time Frame: one year ]
Same as current
Not Provided
Not Provided
 
Open-Label Trial of the Use of Minocycline in the Treatment of Asthma
Open-Label Trial of the Use of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma

The tetracycline minocycline has, in addition to its anti-infective properties, anti-inflammatory properties which may be of use in the treatment of asthma. This study evaluates the benefit of minocycline as add-on therapy for adults with asthma.

Adult asthmatic (ages 18 to 75 years) with a history of moderate to severe persistent asthma are given minocycline capsules as add-on therapy for treatment of asthma. Treatment is for one year. Dosing begins at 150 mg twice daily and can increase every eight weeks by 50mg BID to a maximum of 250 mg twice daily. This is as per patient tolerance as minocycline can cause dizziness and stomach upset, as well as effects of liver enzymes.Patients undergo routine blood toxicity screens every two months, at which time spirometry is performed Exclusion criteria: pregnant women (adequate contraception in mandated) previous history of hypersensitivity to tetracyclines, chronic liver disease Outcome measures: improvement in FEV1 and other spirometric parameters, decrease in oral steroid requirements, change in total serum IgE, improvement in quality of life
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Asthma
Drug: minocycline
add-on therapy: 150 mg bid to 250 mg bid for up to one year
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
20
March 2008
Not Provided

Inclusion Criteria:

  • Adults (ages 18 to 75 yrs)
  • Mild to severe asthma
  • History of or current oral steroid use to control asthma atopy

Exclusion Criteria:

  • Pregnant women
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00536042
open mino
No
Not Provided
State University of New York - Downstate Medical Center
Not Provided
Principal Investigator: Rauno Joks, MD State University of New York - Downstate Medical Center
State University of New York - Downstate Medical Center
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP